Skip to main content

Multiplex Assays Market | Monitoring of Biosimilars in Autoimmune Diseases is Key Opportunity

The global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.17 Billion in 2017, at CAGR of 7.5%. In the current market scenario, there is a growing demand for multiplex assays. The major factors driving the growth of the market include the adoption of Companion Diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays.

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314

Opportunity: Monitoring of biosimilars in autoimmune diseases

Anti-TNF-alpha biologics are proving to be an effective treatment for autoimmune diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). With the increasing healthcare costs as well as patent expirations, the number of R&D activities focusing on the development of biosimilars have increased over the last few years. The launch of biosimilars in the market is increasing the need for the better understanding of potential differences in biosimilar immunogenicity as well as their safety and efficacy profiles as compared to their precursors. For instance, TNF-alpha blockers, such as infliximab and adalimumab, both can trigger immunogenicity responses and researchers have hypothesized that their biosimilars drugs (CT-P13) may also promote immunogenicity. Therefore, it is vital to develop methods for the TDM of biosimilar drugs for autoimmune diseases to ensure effective patient care.

Driver: Use of TDM in traditional anticancer therapies

TDM provides valuable guidance for the dose adjustment of antibiotics, immunosuppressants, antiepileptics, and other drugs. However, its use in traditional anticancer therapies has been limited. The requirement of multiple blood samples to adequately define the systemic exposure of anticancer drugs is the major issue encountered while testing for anticancer therapies.

Drugs in blood samples have a short elimination half-life and are given by intermittent intravenous injections; this makes the entire monitoring process difficult to analyze. However, newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics as compared with traditional cytotoxic drugs. Owing to this, it is now possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many cytotoxic agents, including imatinib, sunitinib, rituximab, and cetuximab.

Although current evidence is not sufficient to make TDM a compulsory practice, investigations with encouraging results will have a practical place in the clinical care of patients with cancer. With the increasing incidence of cancer and focus on reducing the adverse effects of drugs, the monitoring of antineoplastic drugs is expected to gain more importance in the treatment of cancer.

North America is expected to account for the largest market share

North America is expected to account for the largest share of this market, followed by Europe. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

Request Sample Pages @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=61593314

Key Players:

Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Biomérieux, Bühlmann Laboratories, Sekisui Medical, Randox Laboratories.

Comments

Popular posts from this blog

Smoke Evacuation Systems Market: Renewed Growth Opportunities Owing to the Increasing Number of Elective Procedures

  Which are The Key Factors Driving Growth in Smoke Evacuation System Market? Factors such increased product availability of smoke evacuation systems, rising patient preference for minimally invasive surgeries, expansion in the target patient population, and wider acceptance and availability of relevant operating room protocols and guidelines for smoke evacuation systems are the major factors driving the growth of the global smoke evacuation system market. How The Smoke Evacuation Industry Will Grow in Coming Years? The surgical smoke evacuation system market is estimated to grow at a CAGR of 6.6% to reach USD 154 million by 2025 from USD 115 million in 2020. Emerging countries and increasing number of elective surgical procedures. Emerging countries (such as China, India, South Korea, Brazil, and Mexico) offer significant growth opportunities to players operating in the global smoke evacuation systems market. This can be attributed to the increasing public and private i...

Illumina (US), Thermo Fisher (US), and QIAGEN (Netherlands)—Major Players in the Global Epigenetics Market

The global epigenetics market is projected to reach USD 1,605.7 Million by 2022 from USD 854.0 Million in 2017, at a CAGR of 13.5% from 2017 to 2022. Favorable government funding initiatives for epigenetics research, increasing research activities, decreasing sequencing costs & time, and rising prevalence of cancer are the key factors driving market growth Key players in the global epigenetics market, such as Illumina, Thermo Fisher, Diagenode, Merck Millipore, Abcam, Active Motif, New England Biolabs, Agilent, Zymo Research, and PerkinElmer, are focusing on increasing their presence in the high-growth markets through organic as well as inorganic strategies such as product launches, partnerships, agreements, collaborations, expansions, and acquisitions. http://www.marketsandmarkets.com/ResearchInsight/epigenetics-technologies-market.asp Illumina dominated the global epigenetics market in 2016. The company provides sequencing and array-based solutions for ge...

Best Accounting Software to Kick-start the Business for Smaller Firms – Xero

  Xero Accounting Software is an online software mainly designed for the accounting needs of small business firms. The software can be operated from a PC, phone, tablet, or Mac to view the cash flows of the company in real-time. The software is for small business houses and hence it is simple to use yet smart so that the users can devote most of the time in other important areas of their business. USP of This Software: Xero accounting software offers accounting services to small business firms in a smarter way. Some of the USPs of the software the more than 800apps integrated into the software, secure encryption, support system better performance report generation, and others apart from the basic accounting services offered. Best Accounting Software for Medium-Sized Businesses@ https://blog.360quadrants.com/2020/best-accounting-software-for-medium-sized-businesses/ Xero Pricing Xero accounting software offers 30 days of free trial after which you can choose from any of the pri...